BRAF Videos

Monica Niger, MD, National Cancer Institute - MIlan

Videos

Clinical Relevance of BRAF Alterations in Biliary Tract Cancers

08/22/2023

Featuring Monica Niger, MD

At the 2023 World Congress on Gastrointestinal Cancers, Monica Niger, MD, discusses the clinical relevance and actionability of BRAF alterations among patients with advanced biliary tract cancers.

At the 2023 World Congress on...

08/22/2023

Oncology

Yu Sunakawa, MD, St. Marianna University School of Medicine

Videos

Modified FOLFOXIRI Plus Cetuximab as the First-Line Treatment for Patients With RAS Wild-Type Metastatic Colorectal Cancer

07/28/2023

Featuring Yu Sunakawa, MD

At the 2023 ESMO World Congress on Gastrointestinal Cancers, Yu Sunakawa, MD, presented updated survival data from the phase 2 DEEPER trial, evaluating modified(m)-FOLFOXIRI plus cetuximab vs m-FOLFOXIRI plus bevacizumab among patients with...

At the 2023 ESMO World Congress...

07/28/2023

Oncology

Understanding Metastatic MSI-High and MS-Stable Colorectal Cancer

Sponsored

Videos

Understanding Metastatic MSI-High and MS-Stable Colorectal Cancer

03/03/2021

Michael Morse, MD, FACP, MHS, discusses the role that microsatellite stability (MSS) or microsatellite instability (MSI) plays in metastatic CRC.

Michael Morse, MD, FACP, MHS,...

03/03/2021

Oncology

Genomic Features of BRAF and Its Role in the RAS/MAPK Pathway in Colorectal Cancer

Sponsored

Videos

Genomic Features of BRAF and Its Role in the RAS/MAPK Pathway in Colorectal Cancer

03/03/2021

Ryan Corcoran, MD, PhD, discusses the characterization of BRAF mutations and the evolving treatment landscape for patients with BRAF/RAS mutations.

Ryan Corcoran, MD, PhD,...

03/03/2021

Oncology

Exploring HER2 in Metastatic Colorectal Cancer

Sponsored

Videos

Exploring HER2 in Metastatic Colorectal Cancer

02/19/2021

In this video, Christina Wu, MD, discusses HER2 in patients with metastatic CRC.

In this video, Christina Wu, MD,...

02/19/2021

Oncology

The Importance of Biomarker Testing: Carrying Out the Testing Process

Sponsored

Videos

The Importance of Biomarker Testing: Carrying Out the Testing Process

02/19/2021

In part 3 of this video series, Marwan Fakih, MD, discusses how oncologists can make the biomarker testing process understandable for patients with metastatic CRC.

In part 3 of this video series,...

02/19/2021

Oncology

The Importance of Biomarker Testing: Testing Strategies

Sponsored

Videos

The Importance of Biomarker Testing: Testing Strategies

02/19/2021

In part 2 of this video series, Marwan Fakih, MD, discusses testing strategies for detecting mutations in patients with metastatic CRC.

In part 2 of this video series,...

02/19/2021

Oncology

The Importance of Biomarker Testing: Prognostic and Predictive Biomarkers

Sponsored

Videos

The Importance of Biomarker Testing: Prognostic and Predictive Biomarkers

02/17/2021

In part 1 of this video series, Marwan G. Fakih, MD, discusses the role prognostic and predictive biomarkers play in metastatic colorectal cancer.

In part 1 of this video series,...

02/17/2021

Oncology

Videos

Deep Sequencing Impacts Treatment Landscape for MM

01/03/2020

Gareth Morgan, MD, PhD, discusses deep sequencing and how it is improving the treatment landscape for MM.

Gareth Morgan, MD, PhD,...

01/03/2020

Oncology

Videos

Managing Resistance to Third-Generation TKIs in NSCLC

11/22/2019

Lyudmila Bazhenova, MD, talks about understanding, preventing, and delaying EGFR-resistance in the era of osimertinib therapy.

Lyudmila Bazhenova, MD, talks...

11/22/2019

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology